| NCT ID | NCT02357238 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Cleveland Clinic |
| Condition | Uveitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2011-01 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2011-01 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In order to improve the investigators knowledge about uveitis and the underlying mechanism of disease, the investigators propose collecting blood from patients with uveitis, isolating DNA and sequencing the DNA to identify genetic mutations or associations in these patients.
Eligibility Criteria
Inclusion Criteria: * Any patient above with the diagnosis of uveitis. * Any patient with a diagnosis of infectious uveitis such as toxoplasmosis retinochoroiditis, herpes associated retinitis. Exclusion Criteria: * Patients who are unable to give consent * Patients in whom an adequated blood sample can not be obtained.
Contact & Investigator
Sunil K. Srivastava, M.D.
PRINCIPAL INVESTIGATOR
The Cleveland Clinic
Frequently Asked Questions
Who can join the NCT02357238 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, studying Uveitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02357238 currently recruiting?
Yes, NCT02357238 is actively recruiting participants. Contact the research team at baynesk@ccf.org for enrollment information.
Where is the NCT02357238 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT02357238 clinical trial?
NCT02357238 is sponsored by The Cleveland Clinic. The principal investigator is Sunil K. Srivastava, M.D. at The Cleveland Clinic. The trial plans to enroll 1,500 participants.